X-ray Angiography System Market Steady Amid Rising CVD Burden and Policy Headwinds

X-ray Angiography System Market Steady Amid Rising CVD Burden and Policy Headwinds

Date: October 2025
Source: HDIN Research

Market Overview

The global X-ray angiography system market is projected to reach between USD 2.6 billion and 4.2 billion in 2025, with an expected compound annual growth rate (CAGR) of 3.5% to 6.5% through 2030. Growth is driven by increasing demand for cardiovascular diagnostics and interventional procedures.

X-ray angiography plays an essential role in catheter-based therapies for cardiovascular, neurovascular, and peripheral vascular diseases. The system enables real-time fluoroscopic imaging of blood vessels after contrast medium injection, supporting faster diagnosis and minimally invasive treatment.

Key applications include interventional radiology, neuroradiology, cardiology, and surgery. The systems are typically classified into floor-mounted and ceiling-mounted configurations, priced from about USD 200,000 to 2 million depending on configuration and performance.

Major global manufacturers include Siemens Healthineers, GE HealthCare, Philips, Canon Medical, Shanghai United Imaging Medical Technology, Shimadzu, Beijing Wandong Medical Technology, and Lepu Medical.

Public Health Background

According to the World Health Organization, cardiovascular diseases (CVDs) remain the leading cause of death worldwide. In 2022, approximately 19.8 million people died from CVDs, representing 32% of global deaths; 85% of these were caused by heart attack and stroke. Over three-quarters of CVD deaths occurred in low- and middle-income countries. Among the 18 million premature deaths under age 70 caused by noncommunicable diseases in 2021, 38% were due to CVDs.

Early detection and treatment are essential to prevent disease progression. X-ray angiography systems continue to play a central role in enabling timely intervention in emergency and routine clinical settings.

Regulatory and Trade Developments

China:
China continues to promote domestic medical device production. The 2021 “Guidance on Government Procurement of Imported Products” required that 137 categories of medical equipment be sourced entirely from domestic manufacturers. Digital X-ray radiography (DR) systems are among those that must be 100% locally procured.

In 2024, the Chinese government launched a large-scale medical equipment renewal initiative, encouraging hospitals and local health facilities to upgrade systems. The plan targets a 25% increase in overall medical equipment investment by 2027 compared with 2023, with improved access to high-end imaging and diagnostic equipment.

European Union:
The European Commission in 2024 initiated the first investigation under the International Procurement Instrument (IPI), examining barriers to EU suppliers in China’s public procurement market.
On June 20, 2025, the Commission adopted Regulation (EU) 2025/1197, restricting Chinese companies and products from EU public procurement in medical devices. The regulation covers most categories, including diagnostic imaging and surgical systems. As a result, Chinese-origin medical equipment in EU public tenders is expected to decline by 15–20% annually.

United States:
On September 2, 2025, the U.S. Department of Commerce launched a Section 232 investigation into imports of medical devices, PPE, robotics, and industrial machinery, aiming to assess whether these imports pose national security risks.
The probe may lead to new tariffs or import restrictions in 2026, following patterns seen in previous administrations’ trade policies. The investigation has raised concerns among global medtech manufacturers about potential supply chain and pricing disruptions.

Strategic Implications

1. European and U.S. trade policies may limit market access for Chinese suppliers of high-end imaging systems, including X-ray angiography equipment.

2. Global manufacturers with local production capabilities or diversified supply chains are likely to benefit from procurement localization policies.

3. China’s domestic replacement and upgrade programs will stimulate demand for mid- and high-end angiography systems, supporting domestic brands such as United Imaging and Lepu Medical.

4. Market segmentation by region will intensify: Europe and the U.S. may favor local or allied suppliers, while Asia-Pacific, Latin America, and Africa remain open growth markets.

5. The competitive advantage will increasingly depend on system modularity, upgrade flexibility, service networks, and compliance with local procurement rules.